Natera stock trades lower as outlook rises and costs stay high

Published on 11/12/2026 at 16:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Natera stock traded at 285 euros on Thursday afternoon. A higher 2026 revenue outlook is offset by rising investment and continued execution demands.

Outlook Growth Meets Higher Costs

Natera raised its 2026 revenue outlook after stronger testing volumes and improved average selling prices.
Higher spending on staffing, clinical trials and product launches keeps execution central to the investment case.
Management expects positive cash flow while the company continues to report a net loss.

NTRA, US6323071042, Illustration mit AI erstellt.

Natera reported stronger third-quarter growth and raised its full-year revenue outlook in a financial release published on Thursday, November 5. AD HOC NEWS reported that higher testing volumes and improved average selling prices supported the advance.

Natera stock traded at 285.00 euros on Lang & Schwarz at 16:36 CET on Thursday, November 12, 2026. That compares with 289.70 euros on Lang & Schwarz at 13:51 CET in the earlier report on the same day, a decline of 1.62% between the two quotes.

Testing Volume Supports Guidance

Natera processed 1,093,100 tests in the third quarter, up from 893,600 a year earlier. Oncology testing rose to 339,500 units from 211,000, while quarterly revenue reached 794.0 million US dollars, an increase of 34.1% from the prior-year period.

The company now expects 2026 revenue of 3.005 billion to 3.035 billion US dollars, compared with its previous range of 2.850 billion to 2.910 billion US dollars. The midpoint therefore increased by 140 million US dollars. Management also expects a gross margin of 64% to 66% and positive cash flow.

Investment Raises Execution Demands

Operating expenses rose 19.5% to 576.1 million US dollars in the third quarter, mainly because of additional staffing for new products and higher clinical-trial spending. The net loss narrowed to 59.9 million US dollars from 87.5 million US dollars a year earlier, while the diluted loss per share declined to 0.42 US dollars from 0.64 US dollars.

The higher sales target improves visibility, but expanding the testing platform requires continued investment. Volume growth, reimbursement and the rollout of new products remain important factors for investors assessing Natera's earnings path.

The broader US equity market provides the relevant setting for Natera stock; investors can follow the S&P 500 for the overall market environment.

More news and analyses on Natera stock.